Estrogen and Retinoid Regulation of DNA Repair in Breast Cancer

2003 ◽  
Author(s):  
David L. Crowe
Keyword(s):  
Breast Cancer ◽  
Dna Repair

Truncating variants in DNA-repair genes and their effect on AAO of hereditary breast cancer

2018 ◽  
Author(s):  
I Sepahi ◽  
U Faust ◽  
M Sturm ◽  
K Bosse ◽  
M Kehrer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Repair ◽  
Hereditary Breast Cancer ◽  
Dna Repair Genes ◽  
Repair Genes

scholarly journals An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Erica M. Stringer-Reasor ◽  
Jori E. May ◽  
Eva Olariu ◽  
Valerie Caterinicchia ◽  
Yufeng Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Dna Repair ◽  
Pilot Study ◽  
Expression Analysis ◽  
Triple Negative Breast Cancer ◽  
Gene Expression Analysis ◽  
Triple Negative ◽  
Egfr Inhibition ◽  
Link Type

Abstract Background Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA repair, we have previously shown an induced synthetic lethality with combined EGFR inhibition and PARPi. Here, we report the safety and clinical activity of lapatinib and veliparib in patients with metastatic TNBC. Methods A first-in-human, pilot study of lapatinib and veliparib was conducted in metastatic TNBC (NCT02158507). The primary endpoint was safety and tolerability. Secondary endpoints were objective response rates and pharmacokinetic evaluation. Gene expression analysis of pre-treatment tumor biopsies was performed. Key eligibility included TNBC patients with measurable disease and prior anthracycline-based and taxane chemotherapy. Patients with gBRCA1/2 mutations were excluded. Results Twenty patients were enrolled, of which 17 were evaluable for response. The median number of prior therapies in the metastatic setting was 1 (range 0–2). Fifty percent of patients were Caucasian, 45% African–American, and 5% Hispanic. Of evaluable patients, 4 demonstrated a partial response and 2 had stable disease. There were no dose-limiting toxicities. Most AEs were limited to grade 1 or 2 and no drug–drug interactions noted. Exploratory gene expression analysis suggested baseline DNA repair pathway score was lower and baseline immunogenicity was higher in the responders compared to non-responders. Conclusions Lapatinib plus veliparib therapy has a manageable safety profile and promising antitumor activity in advanced TNBC. Further investigation of dual therapy with EGFR inhibition and PARP inhibition is needed. Trial registration ClinicalTrials.gov, NCT02158507. Registered on 12 September 2014

Nrf2 inhibition sensitizes breast cancer stem cells to ionizing radiation via suppressing DNA repair

2021 ◽  
Author(s):  
Shenghui Qin ◽  
Xiaoyuan He ◽  
Houmin Lin ◽  
Bradley A. Schulte ◽  
Mingfeng Zhao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Dna Repair ◽  
Cancer Stem Cells ◽  
Ionizing Radiation ◽  
Breast Cancer Stem Cells

Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer

2017 ◽  
Vol 233 (4) ◽  
pp. 2752-2758 ◽  
Author(s):  
Farimah Beheshti ◽  
Seyed Mahdi Hassanian ◽  
Majid Khazaei ◽  
Mahmoud Hosseini ◽  
Soodabeh ShahidSales ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Repair ◽  
Genetic Variation ◽  
Repair Pathway ◽  
Platinum Based Chemotherapy ◽  
Potential Determinant

scholarly journals Survivin contributes to DNA repair by homologous recombination in breast cancer cells

2015 ◽  
Vol 155 (1) ◽  
pp. 53-63 ◽  
Author(s):  
Eloïse Véquaud ◽  
Grégoire Desplanques ◽  
Pascal Jézéquel ◽  
Philippe Juin ◽  
Sophie Barillé-Nion
Keyword(s):  
Breast Cancer ◽  
Dna Repair ◽  
Homologous Recombination ◽  
Cancer Cells ◽  
Breast Cancer Cells

scholarly journals Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin

2019 ◽  
Vol 109 ◽  
pp. 1541-1546 ◽  
Author(s):  
Zhiwei Zhang ◽  
Caifeng Sun ◽  
Lu Zhang ◽  
Xinming Chi ◽  
Jiamei Ji ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Repair ◽  
Cancer Cells ◽  
Triple Negative Breast Cancer ◽  
Breast Cancer Cells ◽  
Triple Negative
Sign in / Sign up

Export Citation Format

Share Document